Traditional cancer diagnosis typically requires invasive procedures and long waiting periods for results. The LeOPARD project aims to change this by using advanced molecular techniques for swift and accurate diagnoses. The project team wants to develop and implement ultra-rapid molecular cancer diagnostics as decentralized research tools within the DKTK network and to establish a benchmark for their clinical translation and use in future clinical trials. The team incorporates state-of-the-art technologies like nanopore sequencing to provide real-time, comprehensive molecular profiling of tumors, making it suitable for point-of-care applications.

The project focuses on two main approaches:

1. Liquid Biopsy: Using liquid biopsy as a non-invasive method, circulating tumor DNA in body fluids such as blood or cerebrospinal fluid is analyzed. This approach allows for the detection of cancer-specific genetic alterations before surgery. By identifying these genetic markers, the LeOPARD team aims to provide early and precise diagnosis, enabling timely initiation of treatment.

2. Intraoperative Diagnostics: During surgery, a real-time molecular analysis of tissue samples is carried out. This approach enables surgeons to receive immediate feedback on the molecular characteristics of the tumor, guiding them in making informed decisions regarding the extent of surgery and treatment strategies.

In summary, LeOPARD aims to advance cancer diagnostics by equipping clinicians with swift, precise, and molecularly informed data. This steers personalized treatment strategies and improves patient outcomes.